Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 2Unknown 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Breast 3

Conditions

Breast Neoplasms 211Triple Negative Breast Neoplasms 32Stomach Neoplasms 32Inflammatory Breast Neoplasms 21Esophageal Neoplasms 16Carcinoma, Hepatocellular 15Lymphoma, Large B-Cell, Diffuse 9Sarcoma 8Neoplasms 8Non-Muscle Invasive Bladder Neoplasms 6Urinary Bladder Neoplasms 5Pancreatic Neoplasms 5Liver Neoplasms 5Breast Neoplasms, Male 5Adenocarcinoma Of Esophagus 5Ovarian Neoplasms 4Lymphoma 4Testicular Neoplasms 3Primary Breast Cancer 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pathologic Complete Response 3Hemangiosarcoma 3Gallbladder Neoplasms 3Carcinoma, Ductal, Breast 3Unspecified Adult Solid Tumor, Protocol Specific 2Recurrence 2Prostatic Neoplasms 2Osteosarcoma 2Neuroectodermal Tumors, Primitive, Peripheral 2Neoplastic Cells, Circulating 2

Interventions

Paclitaxel 11Carboplatin 8Radiotherapy 7Letrozole 7Cyclophosphamide 7Trastuzumab 5Chemotherapy, Adjuvant 5Doxorubicin 4Brachytherapy 4Albumin-Bound Paclitaxel 4130-nm albumin-bound paclitaxel 4atamestane 3Toremifene 3Tamoxifen 3Radiotherapy, Conformal 3Magnetic Resonance Spectroscopy 3Epirubicin 3Docetaxel 3Cryosurgery 3Cisplatin 3pertuzumab 2Surgical Procedures, Operative 2Radiation 2Lapatinib 2Fulvestrant 2Estrogen Receptor Modulators 2Cryotherapy 2Capecitabine 2Biopsy 2Aromatase Inhibitors 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Carcinoma, Ductal, Breast × Epirubicin × Clear all
NCT02682693 2021-02-02

GeparX

GBG Forschungs GmbH

Phase 2 Completed
780 enrolled
Breast

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

NCT02879513 2020-03-23

Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy

RenJi Hospital

Phase 3 Unknown
290 enrolled
Breast

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

NCT02125344 2017-07-13

A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)

GBG Forschungs GmbH

Phase 3 Completed
961 enrolled
Breast

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡